Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)

Tyrosine kinase inhibitors (TKI) may offer a normal life expectancy to Chronic Myeloid Leukemia (CML) patients. However, a higher than expected incidence of arterial occlusive events (AOEs) was observed during treatment with nilotinib. We previously showed an “inflammatory status” during nilotinib t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sicuranza, Anna, Ferrigno, Ilaria, Abruzzese, Elisabetta, Iurlo, Alessandra, Galimberti, Sara, Gozzini, Antonella, Luciano, Luigiana, Stagno, Fabio, Russo Rossi, Antonella, Sgherza, Nicola, Cattaneo, Daniele, Zuanelli Brambilla, Corrado, Marzano, Cristina, Fava, Carmen, Mulas, Olga, Cencini, Emanuele, Santoni, Adele, Sammartano, Vincenzo, Gozzetti, Alessandro, Puccetti, Luca, Bocchia, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844441/
https://www.ncbi.nlm.nih.gov/pubmed/35178353
http://dx.doi.org/10.3389/fonc.2022.835563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844441/
https://www.ncbi.nlm.nih.gov/pubmed/35178353
http://dx.doi.org/10.3389/fonc.2022.835563

Ejemplares similares